COVID-19大流行期间抗生素使用的影响:现状与未来
本文聚焦2019—20年COVID-19大流行期间全球COVID-19患者中抗菌药物的使用情况,指出全球在数月内使用了大量未报告的抗生素,预期抗菌药物耐药性将明显上升;由于缺乏大流行期间抗菌药物使用的数据,其对新型耐药出现的全球影响尚不清楚,强调该问题应置于公共卫生政策制定与规划的首位。
要点
- COVID-19患者中广泛使用抗生素,全球用量巨大且未充分报告。
- 应预期抗菌药物耐药性明显增加,但全球影响尚不明确。
- 抗菌药物使用与耐药问题应纳入公共卫生政策优先议程。
核心结论
- COVID-19大流行期间全球大量使用抗生素且缺乏数据,预期抗菌药物耐药性将明显上升,其全球影响尚不清楚。
研究设计与样本
- 本文为综述,汇总2019—20年COVID-19大流行期间全球COVID-19患者中抗菌药物使用情况。
主要发现
- COVID-19可表现为严重呼吸道感染,治疗中使用了多种抗病毒药、抗生素和抗真菌药。
- 全球在数月内使用了大量未报告的抗生素,预期抗菌药物耐药性明显增加。
- 因缺乏大流行期间抗菌药物使用数据,对新发耐药的全球影响尚不清楚。
临床怎么用
- 应关注COVID-19患者抗菌药物使用及耐药监测,将抗菌药物管理纳入公共卫生政策与规划。
局限性
- 原文指出缺乏大流行期间抗菌药物使用的数据,全球耐药影响尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 is caused by the SARS-CoV-2 virus, which has infected more than 4 million people with 278 892 deaths worldwide as of 11 May 2020. This disease, which can manifest as a severe respiratory infection, has been declared as a public health emergency of international concern and is being treated with a variety of antivirals, antibiotics and antifungals. This article highlights the administration of antimicrobials in COVID-19 patients worldwide, during the 2019-20 pandemic. It is imperative to be aware of the unreported amounts of antibiotics that have been administered worldwide in just a few months and a marked increase in antimicrobial resistance should therefore be expected. Due to the lack of data about antimicrobial use during this pandemic, the global impact on the emergence of new antimicrobial resistance is as yet unknown. This issue must be at the forefront of public health policymaking and planning in order that we are prepared for the potentially severe consequences for human and animal health and the environment.
引用
- Miranda C, Silva V, Capita R, et al. Implications of antibiotics use during the COVID-19 pandemic: present and future. J Antimicrob Chemother. 2020. PMID: 32830266. doi:10.1093/jac/dkaa350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。